chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The pt received the vaccines on 4/7/99. Was exposed and contracted chicken pox on 2/7/01. Very mild case.
5:30PM-Clearing my throat frequently. 6:00PM-Overwhelming, constant need to cough. Couldn't breathe deeply. Breathing ragged and wheezy. Chest/lungs felt on fire. 6:30PM-Unusual, achy/joint pain throughout body. Cough subsiding. Exhaustion. Felt fine next day. No medication taken during this timeframe.
SEVERE REACTION; This spontaneous report received from a patient via a company representative concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced severe reaction. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of severe reaction was not reported. This report was non-serious.
strong metallic taste in my mouth; felt warm; very lightheaded; Breastfeeding; Breastfeeding; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 31 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm right, administration date 23Apr2021 (Lot number: Unknown) at the age of 31 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "Breastfeeding" (unspecified if ongoing); "arthritis" (unspecified if ongoing); "Foods-oral allergy syndrome" (unspecified if ongoing). Concomitant medication(s) included: TOPICAL [CLOBETASOL PROPIONATE]; PRENATAL VITAMINS [ASCORBIC ACID;BETACAROTENE;CALCIUM SULFATE;COLECALCIFEROL;CYANOCOBALAMIN;FERROUS FUMARATE;FOLIC ACID;NICOTINAMIDE;PYRIDOXINE HYDROCHLORIDE;RETINOL ACETATE;RIBOFLAVIN;THIAMINE MONONITRATE;TOCOPHERYL ACETATE;ZINC OXIDE]. Vaccination history included: Bnt162b2 (1ST DOSE), for COVID-19 IMMUNIZATION. The following information was reported: OFF LABEL USE (non-serious), PRODUCT USE ISSUE (non-serious) all with onset 23Apr2021, outcome "unknown" and all described as "Breastfeeding"; DYSGEUSIA (non-serious) with onset 23Apr2021 09:00, outcome "recovered", described as "strong metallic taste in my mouth"; FEELING HOT (non-serious) with onset 23Apr2021 09:00, outcome "recovered", described as "felt warm"; DIZZINESS (non-serious) with onset 23Apr2021 09:00, outcome "recovered", described as "very lightheaded". Therapeutic measures were not taken as a result of dysgeusia, feeling hot, dizziness.  Additional information: patient received other medications within 2 weeks of vaccinations like Topical creams and prenatal vitamins. patient reported she received her second shot she got strong metallic taste in her mouth, felt warm, and very lightheaded. the feeling disappeared within 5 minutes but was very disconcerting. She did not test since the vaccination, and she did not diagnose as COVID-19 prior to vaccination. No covid prior vaccination. Device Date was 25Apr2021. She had chicken pox booster left arm injection for vaccine received within 4 weeks prior. The most recent COVID-19 vaccine was administered was hospital. No treatment AE.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pt recvd vax 10JAN94 930AM & 10AM pt fainting in classroom; P90, BP 118/66, resp regular & unlabored; pt unconscious approx 30 sec; pt was perspiring, nauseated but oriented x3; dx of poss flu;
Pt mentioned prior history of fainting after IVs. Seemed apprehensive to receive vaccine but did want to receive it. Before being able to apply bandaid to injection site, pt wiped their arm (x2) and had blood on hand. Seemed uncomfortable with sight of blood. Pt was asked to take a seat and wait for 25-30 minutes to be monitored since having prior history of loss of consciousness.  Pt went to waiting area and was walking around when he lost consciousness and fell to the ground. Fell on his back and did not hit his head.  Was able to answer questions about his name/DOB/current date. Pt was immediately responsive and alert. 911 was called. Pt refused medical care other than cold compress and water.  Pt was alert and walking on their own at the time of leaving
After I received the vaccine I felt like I was going to have a panic attack while I was waiting in the chair. My anxieties were already high going in to take the vaccine because I was worried. The next day I started feeling very fatigued, but I kept jumping awake because of the anxiety. I took my temperature and it was between 99-100 degrees. I had a little itchy skin rash, but I'm not sure if it was due to my anxiety. I felt that my anxiety was much higher than normal. The following week I developed stomach issues. I requested that my doctor cut down my metformin mg. My stomach issues went away, so I increased my metformin again. I started feeling better after week 3. I cut back down to 500mg again and started taking a probiotic again. I am starting to feel like I'm having flu like symptoms this week.
Information has been received from a health professional concerning a 65 year old female with no pertinent medical history who on 13JAN2004 was vaccinated with a 0.5 ml dose of pneumococcal 23v polysaccharide vaccine. On 13JAN2004 the pt developed "swelling, itching and hot around injection site". The pt was told to put ice on the affected area. The outcome is unknown at this time. Unspecified medical attention was sought. There was no product quality complaint. No lab diagnostic studies were performed. The reporter also indicated that three other pts were vaccinated with a dose of pneumococcal 23v polysaccharide vaccine. Additional info has been requested.
Patient/Father lied about DOB and consequently the pharmacist to an 11 year old when pfizer is only approved for 12 and up. Patient reports no adverse effects from vaccine
This is a spontaneous report received from a non-contactable reporter(s) (Pharmacist). The reporter is the patient.  A 47 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Mar2021 (Lot number: ER8727) as dose 1, single and administered in arm left, administration date 14Apr2021 (Lot number: EP7533) as dose 2, single for covid-19 immunisation. Relevant medical history included: "Environmental allergies" (unspecified if ongoing); "Raynauds bradycardia" (unspecified if ongoing); "Penicillin" (unspecified if ongoing); "bradycardia" (unspecified if ongoing). Concomitant medication(s) included: TYLENOL; FAMOTIDINE; LORATADINE.  The following information was reported: COVID-19 (medically significant), VACCINATION FAILURE (medically significant) all with onset 27Nov2021, outcome "recovering" and all described as "Positive COVID-19 test on 27Nov2021."; COUGH (non-serious) with onset 22Nov2021, outcome "recovering", described as "slight cough"; PAIN (non-serious) with onset 22Nov2021, outcome "unknown", described as "body aches"; PYREXIA (non-serious) with onset 22Nov2021, outcome "recovering", described as "mild fever"; SINUS PAIN (non-serious) with onset 22Nov2021, outcome "recovering", described as "sinus pressure/pain,"; SNEEZING (non-serious) with onset 22Nov2021, outcome "recovering", described as "sneezing"; RHINORRHOEA (non-serious) with onset 22Nov2021, outcome "recovering", described as "runny nose"; FATIGUE (non-serious) with onset 22Nov2021, outcome "recovering", described as "fatigue". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (22Nov2021) negative; (27Nov2021) positive, notes: Nasal swab. Therapeutic measures were not taken as a result of covid-19, vaccination failure, cough, pain, pyrexia, sinus pain, sneezing, rhinorrhoea, fatigue.; Sender's Comments: Based on plausible dose -event relationship post vaccination and no other alternate explanation the causal role of BNT162B2 cannot be excluded for the reported events
Patient became highly febrile, passed out at work, went to ED and got IV fluids.
I went in for a check up and found that my hemoglobin. The doctor completed more blood test and asked me to get a colonoscopy completed. I have that scheduled for April 27, 2022. I had already done a Cologuard which was positive.
Fever 102 within 12 hours of vaccine, swelling within 12 hours of vaccine, Tylenol, Motrin, ice.
I woke up and realized I was congested.  When I came into port and back home I and my wife took a  COVID-19 Test-Positive.  I went to seen my Doctor who suggested I was at the end of my illness so no prescriptions were ordered.  I tested clear of COVID-19 on 16APR2023
report the administration of a pediatric Engerix-B dose to a 60-year-old patient; report the administration of a pediatric Engerix-B dose to a 60-year-old patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 60-year-old male patient who received HBV (Engerix B pediatric) (batch number 25N39, expiry date 16-MAR-2024) for prophylaxis.   On 18-OCT-2023, the patient received Engerix B pediatric. On 18-OCT-2023, an unknown time after receiving Engerix B pediatric, the patient experienced adult use of a child product (Verbatim: report the administration of a pediatric Engerix-B dose to a 60-year-old patient) and underdose (Verbatim: report the administration of a pediatric Engerix-B dose to a 60-year-old patient). The outcome of the adult use of a child product and underdose were unknown.   Additional Information: GSK receipt date 20 Oct 2023 A pharmacist called to report the administration of a pediatric Engerix-B dose to a 60-year-old patient. The HCP asked for guidance on this situation, which led to adult use of a child product and underdose . The reporter did not consent to follow-up.
Folowing shot, I noted feeling lightheadedness and full body tingling. This escalated to my sinuses draining and continued tightness. This went on for 30 minutes, staff on site was aware. I was offered Epinepherine pen, but refused.  I was monitored for another hour and went home as symptoms began to slowly resolve. Once I got home, I did have residual itchy throat and felt swollen on the morning after at 12pm. I took 100 mg of Benadryl and found my symptoms completely resolved.
Vascular occlusion; Blanching of skin; Bruising; This spontaneous case was reported by a nurse and describes the occurrence of CONTUSION (Bruising) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Gastric bypass. Concurrent medical conditions included Rheumatoid arthritis. Concomitant products included BOTULINUM TOXIN TYPE A HAEMAGGLUTININ COMPLEX (DYSPORT), HYALURONIC ACID (RESTYLANE), DURAPATITE (RADIESSE), LIDOCAINE and VORHYALURONIDASE ALFA (HYLENEX) for an unknown indication.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Feb-2021, the patient experienced CONTUSION (Bruising). The patient was treated with MULTIVITAMINS [VITAMINS NOS] at an unspecified dose and frequency. At the time of the report, CONTUSION (Bruising) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient had history of fillers or toxins.   Most recent FOLLOW-UP information incorporated above includes: On 17-May-2021: Non significant follow up received on 17-MAY-2021, no new information On 16-Jul-2021: reporter provided causality
Initial case received on 05 November 2010 from a healthcare professional. An 18 month old child received on an unspecified date a 0.5 cc single dose syringe injection of FLUZONE (lot number 3620DA). The patient experienced salmonella after vaccination in an unknown time frame. The reporter had no further information since the patient was vaccinated in another facility. Outcome was unknown. Documents held by sender: None.
Nausea/she feels like she may vomit; Severe headache; This spontaneous case was reported by a consumer and describes the occurrence of HEADACHE (Severe headache) and NAUSEA (Nausea/she feels like she may vomit) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Mar-2021, the patient experienced HEADACHE (Severe headache). On 11-Mar-2021, the patient experienced NAUSEA (Nausea/she feels like she may vomit). The patient was treated with PARACETAMOL (TYLENOL) at a dose of UNK dosage form, q4h. On 11-Mar-2021, HEADACHE (Severe headache) had resolved. At the time of the report, NAUSEA (Nausea/she feels like she may vomit) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Extensive swelling & itching at injection site. Large hard, hot, painful lump in upper arm where injected.
CONFUSION, POOR BALANCE, SWEATING. ALL DUE TO HYPOGLYCEMIA. BG WAS EVALUATED TO BE 40
This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (hurting bad her left arm), HEADACHE (headaches) and VACCINATION SITE PAIN (starting hurting her right arm at the site injection) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included Arthritis, Cancer and Gout. Concurrent medical conditions included Blood pressure high. Concomitant products included TRAMADOL, L-THYROXINE [LEVOTHYROXINE], ALLOPURINOL, AMLODIPINE MALEATE (MELODIPINE), DICYCLOMINE [DICYCLOVERINE], LISINOPRIL, PANTOPRAZOLE, BIOTIN and BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT) for an unknown indication.    On 06-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-Jan-2021, the patient experienced HEADACHE (headaches). On 07-Jan-2021, the patient experienced VACCINATION SITE PAIN (starting hurting her right arm at the site injection). On 08-Jan-2021, the patient experienced PAIN IN EXTREMITY (hurting bad her left arm). At the time of the report, PAIN IN EXTREMITY (hurting bad her left arm), HEADACHE (headaches) and VACCINATION SITE PAIN (starting hurting her right arm at the site injection) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment medication not provided by reporter.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of these events, a causal relationship cannot be excluded.
Patient awoke the morning after vaccination with severe tinnitus, worse in the left ear.  She was evaluated by ENT approximately 2 weeks after symptom onset.  At that time, there was no improvement in the symptoms.  Audiogram was performed.  Patient was found to have high frequency hearing loss.  No baseline audiogram was available for comparison.   She had no known hearing loss history.  Patient was re-evaluated approximately 2 months s/p vaccination, with persistent symptoms.  No improvement to date.
Spotty rash on immunization arm.   Patient is taking diphenhydramine to help with the allergic reaction.
A WEEK AFTER GIVING THE JOHNSON AND JOHNSON VACCINE PATIENT BEGAN TO PRESENT SYMPTOMS OF ANXIETY, INCOHERENT SPEECH, HALLUCINATION, INSOMNIA AND NO APPETITE.
Information has been received from a health professional concerning a 5 yr old pt who in 1999, at 12 months of age, was vaccinated with a dose of varicella virus vaccine live. In approx 2004, the child experienced a mild case of breakthrough, noted to be approx 12 pox and a very mild case. The pt fully recovered. No hospitalizations were noted. Additional information has been requested.
received the vaccine about 3pm 6/7/07 at KSU, at 11 am today, chills and muscle aches, shortness of breath, severe fatigue set in temp elevated to 102degrees, muscle aches worsened, he fell asleep, woke up at 2pm, at 3pm I arrived home he was sleeping, I woke him, 101 fever, aches, called Dr. to report. gave him tylenol,and fluids, aches and fever continue off and on at this time.
This spontaneous report as received from a registered nurse refers to a 60 year old female patient with no pertinent medical history and no drug reactions or allergies. On 03-MAY-2013, the patient was vaccinated with a single dose of ZOSTAVAX (Lot # J000432, expiration date 10-APR-2014) SQ. Concomitant therapies included iron (unspecified). The nurse reported that on 04-MAY-2013, the patient developed lesions on the right side of her forehead and scalp. The patient was evaluated in the office on 06-MAY-2013 and was diagnosed with shingles. The patient was prescribed VALTREX 500 mg three times per day for 3 weeks. There were no Lab diagnosis or studies performed. The outcome of shingles was reported as not recovered/not resolved. Additional information has been requested.
tested positive for COVID-19; tested positive for COVID-19; This is a spontaneous report from a contactable consumer (patient son) reported for a female (mother) patient of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot number and Expiration dates were unknown), via subcutaneous route of administration, on 10Mar2021 as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. It reported that, the consumers mom (patient) received first dose of the COVID-19 vaccine on 10Mar2021. The patient tested positive for COVID-19 after COVID-19 vaccine. She was scheduled to take the second dose of the vaccine on 31Mar2021. However, her doctor recommends to postpone the second dose of the vaccine since she has COVID-19. The patient underwent lab tests and procedures which included SARS-COV-2 test: positive on an unspecified date. The outcome of the patient event was unknown.  Information on the lot/batch number has been requested.
Less than 48 hours after vaccination a rash  appeared on the inside of my right elbow. It?s now 4 days out and it?s gotten slightly worse. It looks like eczema, tiny red blisters. It itches and stings a bit.
Wrong dosage was given. Patient over 65 should have recieved Fluzone High Dosage for over 65 years old.
Within an hour after injection, severe pain over entire body and chills were experienced immobilizing patient (bed-ridden) for over a week. A trip to Dr. resulted in hospitalization due to adv. reaction.
red rash on his arms, face, back and legs.; fever of 101F; fatigue; excruciating headache; swollen hands; loss of appetite; This case was reported by a consumer via call center representative and described the occurrence of red rash in a 72-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 18th August 2019, the patient received the 1st dose of Shingrix. In August 2019, less than a day after receiving Shingrix, the patient experienced fever, fatigue, headache, hand swelling and appetite lost. On 18th August 2019, the patient experienced red rash. The patient was treated with paracetamol (Tylenol), benadryl (nos) (Benadryl) and steroids nos (Steroids). On an unknown date, the outcome of the red rash was unknown and the outcome of the fever, fatigue, headache, hand swelling and appetite lost were recovered/resolved.   It was unknown if the reporter considered the red rash, fever, fatigue, headache, hand swelling and appetite lost to be related to Shingrix.  Additional details were reported as follows: The case was reported by patient himself. At the time of reporting, the patient used continuous positive airway pressure (CPAP) machine. In the evening after receiving Shingrix, the patient experienced a red rash on his arms, face, back and legs.  The patient also developed fever of 101degrees F, excruciating headache, fatigue, and loss of appetite.  The patient's states hands were swollen, but he was not sure if they were actually swollen. The patient received treatment with Tylenol for the fever and headache. The patient also received Benadryl for rash. On the day of reporting, the patient started treatment with steroids. The patient's doctor advised him not to receive the 2nd dose of Shingrix. The reporter consented to follow up. The reporter did not provide any additional details.
Left arm swelling (bicep area), redness, tenderness, and warm to touch. 3 day time course and totally gone 1 week later.
A non-serious spontaneous report of post-nasal drip taste, bad cold, sneezing, and running nose has been received from a female patient of unknown age subsequent to FLUMIST.  No medical history or concomitant medications were provided.  The patient received FLUMIST on an unknown date.  A consumer reported her experience after receiving FLUMIST.  Per the reporter, initially, there was no reaction but then she developed a post-nasal drip taste, the next day and three days after she had sneezing and runny nose; "it felt like I had gotten a bad cold".  The patient had not received a flu immunization in 15 years.  Outcome was not reported.  Per the reporter, she will take the shot next time.
got hives, nausea, diarrhea, from knee down feels like carrying a ton of weights
Case number PHEH2016US033075, is an initial spontaneous report received from a medical assistant on 15 Dec 2016. This report refers to a 50 years old female patient. Prior vaccination history included vaccination with influenza vaccine (unknown whether seasonal or pandemic, other manufacturer) with no side effects (well tolerated). Current condition included drug allergies with ADIPRA, ibuprofen, NOVOLOG and VALIUM. Concomitant medications were not reported. The patient was vaccinated with a single dose of FLUCELVAX (batch number: 185325A, expiry date: Apr 2017) at a dose of 0.5 ml intramuscularly into left deltoid on 14 Dec 2016 11.16 AM. The patient was also vaccinated with ENGERIX B (manufacturer unknown, batch number: 3SG7C) at a dose of 40 mcg into right deltoid on 14 Dec 2016 11.16 AM. The medical assistant stated that, the first excursion occurred with 57 degrees F for 14.5 hours for prefilled syringe (PFS) FLUCELVAX. One FLUCELVAX was administered to a patient. The medical assistant upon follow up reported that the patient was doing well and no adverse reactions were reported following this administration error. Follow up received from a medical assistant on 06 Jan 2017: Updated reporter details (fax number), added prior vaccination history, current condition (drug allergies), updated the dosage regimen anatomical location for FLUCELVAX and time of administration, added co-suspect vaccine (ENERGIX B), and updated the reporter's comment.
PT HAD EXPERIENCE MILD TO MODERATE MUSCLE PAIN ON INJECTION SITE (LEFT ARM), IT HAD LASTED SINCE THE DATE SHE RECEIVED THE VACCINE TO NOW. THE PAIN INTENSIFIED MOSTLY IN THE MORNING AND EVENING.
12/7/2016 Patient received Varicella subcutaneous in right arm and MMR subcutaneous and MENACTRA IM in left arm. Patient woke the next morning with a "hot" rash on forehead, cheeks, bridge of nose and behind her right upper arm. She was seen that day by a medical doctor. The provider also noted one lesion at the injection site. The patient denied any shortness of breath or cough. No itching in the throat or mouth. The provider treated her with Alavert and Benadryl. The patient was instructed to take one Alavert in the AM and 2 Benadrly in the PM.